Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?

Leukemia Research

Volumn 50, Issue , 2016, Pages 46-49

  Nakaya, Aya ^a   Fujita, Shinya ^a   Satake, Atsushi ^a   Nakanishi, Takahisa ^a   Azuma, Yoshiko ^a   Tsubokura, Yukie ^a   Hotta, Masaaki ^a   Yoshimura, Hideaki ^a   Ishii, Kazuyoshi ^a   Ito, Tomoki ^a   Nomura, Shosaku ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carrier; Delayed reactivation; Reactivation; Resolved occult HBV infection; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; VIRUS REACTIVATION; VIRUS REPLICATION; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PRACTICE GUIDELINE; PREMEDICATION; RECURRENT DISEASE; STANDARDS; TIME FACTOR; VIROLOGY; VIRUS ACTIVATION;

DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PREMEDICATION; RECURRENCE; RITUXIMAB; TIME FACTORS; VIRUS ACTIVATION;

EID: 84988528118     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2016.09.014     Document Type: Article

References (10)

1. [1] Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology, JSH guidelines for the management of hepatitis B virus infection. Hepatol. Res. 44 (2014), 1–58.
2. [2] Lok, A.S., McMahon, B.J., Chronic hepatitis B: update 2009. Hepatology 50 (2009), 661–662.
3. [3] European Association For The Study Of The Live, EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57 (2012), 167–185.
4. [4] Liaw, Y.F., Kao, J.H., Piratvisuth, T., Chan, H.L., Chien, R.N., Liu, C.J., et al. Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 4 (2012), 809–810.
5. [5] Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig. Liver Dis. 39 (2007), 397–408.
6. [6] Reddy, K.R., Beavers, K.L., Hammond, S.P., Lim, J.K., Falck-Ytter, Y.T., et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 215–219.
7. [7] Hashimoto, Y., Suzuki, F., Hirakawa, M., Kawamura, Y., Yatsuji, H., Sezaki, H., Hosaka, T., et al. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J. Med. Virol. 82 (2010), 684–691.
8. [8] Huang, Y.H., Hsiao, L.T., Hong, Y.C., Chiou, T.J., Yu, Y.B., Gau, J.P., Liu, C.Y., Yang, M.H., et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis, B. J. Clin. Oncol. 31 (2013), 2765–2772.
9. [9] Seto, W.K., Chan, T.S., Hwang, Y.Y., et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. JCO 32 (2014), 3736–3743.
10. [10] Kusumoto, S., Tanaka, Y., Suzuki, R., et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin. Infect. Dis. 61 (2015), 719–729.